Annual CFO
-$90.97 M
+$6.08 M+6.27%
December 31, 2023
Summary
- As of February 12, 2025, FULC annual cash flow from operations is -$90.97 million, with the most recent change of +$6.08 million (+6.27%) on December 31, 2023.
- During the last 3 years, FULC annual CFO has fallen by -$37.31 million (-69.54%).
- FULC annual CFO is now -353.15% below its all-time high of -$20.07 million, reached on December 31, 2017.
Performance
FULC Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$19.07 M
-$77.97 M-132.38%
September 30, 2024
Summary
- As of February 12, 2025, FULC quarterly cash flow from operations is -$19.07 million, with the most recent change of -$77.97 million (-132.38%) on September 30, 2024.
- Over the past year, FULC quarterly CFO has increased by +$4.09 million (+17.64%).
- FULC quarterly CFO is now -132.38% below its all-time high of $58.90 million, reached on June 30, 2024.
Performance
FULC Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$8.62 M
+$3.83 M+30.80%
September 30, 2024
Summary
- As of February 12, 2025, FULC TTM cash flow from operations is -$8.62 million, with the most recent change of +$3.83 million (+30.80%) on September 30, 2024.
- Over the past year, FULC TTM CFO has increased by +$82.35 million (+90.53%).
- FULC TTM CFO is now -29.90% below its all-time high of -$6.63 million, reached on March 31, 2018.
Performance
FULC TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
FULC Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +6.3% | +17.6% | +90.5% |
| 3 y3 years | -69.5% | +17.6% | +90.5% |
| 5 y5 years | -303.2% | +17.6% | +90.5% |
FULC Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -15.9% | +6.3% | -132.4% | +31.6% | at high | +91.3% |
| 5 y | 5-year | -130.4% | +6.3% | -132.4% | +31.6% | at high | +91.3% |
| alltime | all time | -353.1% | +6.3% | -132.4% | +31.6% | -29.9% | +91.3% |
Fulcrum Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$19.07 M(-132.4%) | -$8.62 M(-30.8%) |
| Jun 2024 | - | $58.90 M(-332.9%) | -$12.45 M(-86.5%) |
| Mar 2024 | - | -$25.28 M(+9.2%) | -$92.13 M(+1.3%) |
| Dec 2023 | -$90.97 M(-6.3%) | -$23.16 M(+1.1%) | -$90.97 M(+4.0%) |
| Sep 2023 | - | -$22.91 M(+10.2%) | -$87.50 M(-5.4%) |
| Jun 2023 | - | -$20.79 M(-13.8%) | -$92.48 M(-6.6%) |
| Mar 2023 | - | -$24.12 M(+22.4%) | -$99.06 M(+2.1%) |
| Dec 2022 | -$97.05 M(+23.7%) | -$19.70 M(-29.4%) | -$97.05 M(-2.2%) |
| Sep 2022 | - | -$27.88 M(+1.9%) | -$99.21 M(+5.7%) |
| Jun 2022 | - | -$27.37 M(+23.8%) | -$93.90 M(+11.3%) |
| Mar 2022 | - | -$22.11 M(+1.1%) | -$84.36 M(+7.5%) |
| Dec 2021 | -$78.48 M | -$21.86 M(-3.2%) | -$78.48 M(+2.7%) |
| Sep 2021 | - | -$22.57 M(+26.7%) | -$76.45 M(+31.0%) |
| Jun 2021 | - | -$17.82 M(+9.8%) | -$58.38 M(+6.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | -$16.23 M(-18.2%) | -$54.68 M(+1.9%) |
| Dec 2020 | -$53.66 M(+35.9%) | -$19.83 M(+340.2%) | -$53.66 M(+40.0%) |
| Sep 2020 | - | -$4.50 M(-68.1%) | -$38.32 M(-18.2%) |
| Jun 2020 | - | -$14.12 M(-7.1%) | -$46.84 M(+4.6%) |
| Mar 2020 | - | -$15.20 M(+238.2%) | -$44.79 M(+13.4%) |
| Dec 2019 | -$39.48 M(+75.0%) | -$4.50 M(-65.5%) | -$39.48 M(-4.6%) |
| Sep 2019 | - | -$13.02 M(+7.8%) | -$41.39 M(+27.4%) |
| Jun 2019 | - | -$12.07 M(+22.0%) | -$32.49 M(+25.8%) |
| Mar 2019 | - | -$9.90 M(+54.6%) | -$25.83 M(+14.5%) |
| Dec 2018 | -$22.56 M(+12.4%) | -$6.40 M(+55.4%) | -$22.56 M(+39.6%) |
| Sep 2018 | - | -$4.12 M(-23.8%) | -$16.16 M(+34.2%) |
| Jun 2018 | - | -$5.41 M(-18.5%) | -$12.04 M(+81.5%) |
| Mar 2018 | - | -$6.63 M | -$6.63 M |
| Dec 2017 | -$20.07 M | - | - |
FAQ
- What is Fulcrum Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Fulcrum Therapeutics?
- What is Fulcrum Therapeutics annual CFO year-on-year change?
- What is Fulcrum Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Fulcrum Therapeutics?
- What is Fulcrum Therapeutics quarterly CFO year-on-year change?
- What is Fulcrum Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Fulcrum Therapeutics?
- What is Fulcrum Therapeutics TTM CFO year-on-year change?
What is Fulcrum Therapeutics annual cash flow from operations?
The current annual CFO of FULC is -$90.97 M
What is the all time high annual CFO for Fulcrum Therapeutics?
Fulcrum Therapeutics all-time high annual cash flow from operations is -$20.07 M
What is Fulcrum Therapeutics annual CFO year-on-year change?
Over the past year, FULC annual cash flow from operations has changed by +$6.08 M (+6.27%)
What is Fulcrum Therapeutics quarterly cash flow from operations?
The current quarterly CFO of FULC is -$19.07 M
What is the all time high quarterly CFO for Fulcrum Therapeutics?
Fulcrum Therapeutics all-time high quarterly cash flow from operations is $58.90 M
What is Fulcrum Therapeutics quarterly CFO year-on-year change?
Over the past year, FULC quarterly cash flow from operations has changed by +$4.09 M (+17.64%)
What is Fulcrum Therapeutics TTM cash flow from operations?
The current TTM CFO of FULC is -$8.62 M
What is the all time high TTM CFO for Fulcrum Therapeutics?
Fulcrum Therapeutics all-time high TTM cash flow from operations is -$6.63 M
What is Fulcrum Therapeutics TTM CFO year-on-year change?
Over the past year, FULC TTM cash flow from operations has changed by +$82.35 M (+90.53%)